DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationasthmaAIRMARTinhalers

Stepwise maintenance treatment of adult asthma

Essential points for quick revision.

!
Escalate

A maintenance plan does not manage an acute severe attack. Marked breathlessness, inability to speak normally, PEF at or below 50% best/predicted, hypoxaemia, exhaustion or poor response to the person's reliever plan requires same-day emergency assessment; call 999 for life-threatening features.

Synopsis

Use the current UK ICS/formoterol-first pathway, fix modifiable causes before stepping up, and escalate or step down with explicit review points, device-specific doses and steroid-safety checks.

  • Confirm asthma objectively where possible and check inhaler technique, adherence, smoking, triggers and comorbidity before every step up.
  • Adults and people aged 12 or over with infrequent symptoms should be offered low-dose ICS/formoterol as-needed anti-inflammatory reliever (AIR), not SABA alone.
  • If newly diagnosed and highly symptomatic, or presenting with a severe exacerbation, start low-dose maintenance-and-reliever therapy (MART) rather than AIR alone.

Key red flags

High future risk

Previous ICU/intubation, recent hospital attendance, repeated oral steroids, poor adherence, excess SABA collection, psychosocial barriers, food allergy or low lung function can confer risk even when daily symptoms seem modest.

Investigation priorities

01
Asthma Control Test/Questionnaire plus attack historyFirst step

Measure current impairment and future risk separately.

Management branches

Preferred pathwayAIR to MART to specialist

Confirmed asthma in an adult or person aged 12 years or over.

  1. 1. Infrequent symptoms: offer low-dose ICS/formoterol as needed (AIR), teach device use and give a personalised action plan. Do not add routine SABA to an AIR/MART plan unless a specialist-defined exception applies.
  2. 2. If AIR does not control asthma, or at diagnosis symptoms are highly symptomatic/recently exacerbating, use low-dose MART: scheduled low-dose ICS/formoterol plus the same inhaler when needed.

Key medicines

Budesonide/formoterol low-dose AIR (example device)Delivered 160/4.5 micrograms per inhalation: 1 inhalation when needed; if symptoms persist after a few minutes take 1 more. Maximum 6 on one occasion; more than 8 in a day is not normally needed and up to 12/day is only for a limited period under the SmPC.
Budesonide/formoterol low-dose MART (example device)Delivered 160/4.5 micrograms: commonly 1 inhalation twice daily (or 2 once daily) plus 1 inhalation as needed; total above 8/day is not normally needed, absolute product maximum 12/day for a limited period.
Open full textbook Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom